Sensei Biotherapeutics, Inc. (SNSE)

AI-Powered SEC Filing Analysis

Insider Trading Filed: 2026-04-14

Key Insights

Phillip B. Donenberg, a director of Sensei Biotherapeutics, Inc. (SNSE), received a supplemental stock option grant of 23,100 shares with a vesting period of 3 years, aligning his total initial director option grant with the company's non-employee director compensation policy.
The supplemental option grant has an exercise price of $29.89 per share and will expire on April 9, 2036, indicating the company is compensating its directors competitively to incentivize their long-term commitment.
The filing suggests Sensei Biotherapeutics is focused on retaining its board members and aligning their interests with those of shareholders through equity-based compensation.

Insider Trading Filed: 2026-04-14

Key Insights

Josiah Craver, the Principal Financial Officer and Principal Accounting Officer, acquired 80,000 stock options at an exercise price of $29.89 on April 10, 2026, indicating his belief in the company's long-term growth potential.
The options vest over a 4-year period, with 25% vesting on the first anniversary and the remainder vesting monthly thereafter, aligning Craver's incentives with the company's long-term performance.
The significant number of options acquired by the company's senior financial officer suggests that Sensei Biotherapeutics' management is confident in the company's future prospects and is willing to invest their own capital in the business.

Get real-time filing analysis in the app

Download on the App Store

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.